Zydus Lifesciences Limited — Updates, 18-03-2025: Press Release

Zydus Lifesciences has received final approval from the USFDA for the manufacture of Apalutamide Tablets (60 mg), a treatment for metastatic castration-sensitive prostate cancer. The tablets will be produced at the company's facility in SEZ, Ahmedabad. This approval is significant as Apalutamide had annual sales of approximately USD 1,099.8 million in the US as of January 2025, highlighting a lucrative market opportunity. The total count of approvals for Zydus now stands at 420, with 483 Abbreviated New Drug Applications (ANDAs) filed since FY 2003-04. This development enhances Zydus's product portfolio and positions the company favorably in the oncology segment, suggesting a positive outlook for future revenue growth.